The first inhalable insulin Afrezza in the U.S markets launched by SanofiDaniel McCarthy (Author) Published Date : Feb 03, 2015 09:08 IST
A prospective advance in deteriorating diabetes drug sales and for a better quality of life for the patient, Sanofi has commenced the availability of insulin which comes in form of an inhaler instead of an inject-able one as per conventional methods.This new formed drug has been developed by Mankind. Corp, Afrezza and is said to be the only inhalable insulin to be available in the U.S market with two competitors but that in the field of inject-able insulin and they are Eli Lilly and Novo Nordisk for Sanofi.
The inhaling insulin is supposed to act faster and is more convenient compared to traditional ones although inhaled products has a history of failure and thus there are concerns and probable risks in association with this new way of in-taking insulin.FDA approved Afrezza uses a whistle-sized inhaler and assists in controlling blood sugar in both type 1 and 2 and has been developed under the guidance of Pfizer's rival Exubera. Back in 2006, Exubera was approved with the hope of $2 billion sales annually but unfortunately the product was too heavy and the patients were trifled away by the need of a periodic lung function examinations and hence it was ultimately taken out of the market.
Valued at $7.54 for a daily dosage of 12 units, Afrezza is costlier than $3.14 Apidra, which is the inject-able correspondent in Sanofi's drugs establishment. Although Afrezza is not be used by patients with conditions of asthma, other complications and als0 not suggested for smokers.Even with all the restrictions Afrezza is anticipated to make sales of around $182 million by 2019 as depicted by Thomson Reuters Cortellis.
Sanofi's diabetes sector engenders about $7 billion of sales per year and around 30% of group profits, but the patent on its Lantus insulin, the most prescribed insulin globally, expires in 2015, and it anticipates slight or no sales growth throughout 2018. Last year a Sanofi executive was fired due to bad performance in the diabetes sector and therefore the company is gambling on Afrezza and enhanced versions of their other medicines.
The first inhalable insulin Afrezza in the U.S markets launched by Sanofi